MA27105A1 - Nouveaux composes - Google Patents

Nouveaux composes

Info

Publication number: MA27105A1
Authority: MA; Morocco
Prior art keywords: new compounds; compounds; new
Prior art date: 2002-03-06

Application number

MA27806A

Other languages

English (en)

Inventor

Peter Aranyi

Laszlo Balazs

Imre Bata

Sandor Batori

Eva Baronkay

Philippe Bovy

Karoly Kanai

Zoltan Kapui

Edit Suzan

Tibor Szabo

Lajos T Nagy

Katalin Urban-Szabo

Marton Varga

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-06

Filing date

2004-07-29

Publication date

2004-12-20

2004-07-29 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

2004-12-20 Publication of MA27105A1 publication Critical patent/MA27105A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Hematology (AREA)
Obesity (AREA)
Virology (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Child & Adolescent Psychology (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Anesthesiology (AREA)
Cardiology (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)

MA27806A 2002-03-06 2004-07-29 Nouveaux composes MA27105A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HU0200849A HUP0200849A2 (hu)	2002-03-06	2002-03-06	N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra

Publications (1)

Publication Number	Publication Date
MA27105A1 true MA27105A1 (fr)	2004-12-20

Family

ID=90001540

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA27806A MA27105A1 (fr)	2002-03-06	2004-07-29	Nouveaux composes

Country Status (28)

Country	Link
US (3)	US7348327B2 (fr)
EP (1)	EP1487807B1 (fr)
JP (1)	JP4559737B2 (fr)
KR (1)	KR100977898B1 (fr)
CN (2)	CN1639159A (fr)
AR (1)	AR038868A1 (fr)
AT (1)	ATE443054T1 (fr)
AU (1)	AU2003209514B2 (fr)
BR (1)	BR0307960A (fr)
CA (1)	CA2475312C (fr)
DE (1)	DE60329282D1 (fr)
EA (1)	EA007410B1 (fr)
EC (1)	ECSP045274A (fr)
HR (1)	HRP20040910A2 (fr)
HU (1)	HUP0200849A2 (fr)
IL (2)	IL163286A (fr)
IS (1)	IS7434A (fr)
MA (1)	MA27105A1 (fr)
MX (1)	MXPA04008613A (fr)
NO (1)	NO20044221L (fr)
NZ (1)	NZ535662A (fr)
PL (1)	PL371099A1 (fr)
RS (1)	RS79004A (fr)
TN (1)	TNSN04141A1 (fr)
TW (1)	TWI250978B (fr)
UA (1)	UA78291C2 (fr)
WO (1)	WO2003074500A2 (fr)
ZA (1)	ZA200406467B (fr)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE370943T1 (de) *	2001-06-27	2007-09-15	Smithkline Beecham Corp	Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren
HUP0202001A2 (hu) *	2002-06-14	2005-08-29	Sanofi-Aventis	DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok
TW200401635A (en) *	2002-07-23	2004-02-01	Yamanouchi Pharma Co Ltd	2-Cyano-4-fluoropyrrolidine derivative or salt thereof
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20040242568A1 (en)	2003-03-25	2004-12-02	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
JP4806628B2 (ja)	2003-05-05	2011-11-02	プロビオドルグエージー	グルタミニルシクラーゼ阻害剤
WO2004103993A1 (fr)	2003-05-14	2004-12-02	Syrrx, Inc.	Inhibiteurs de dipeptidyl peptidase
US20050070531A1 (en)	2003-08-13	2005-03-31	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
HU227684B1 (en) *	2003-08-29	2011-11-28	Sanofi Aventis	Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
NZ546887A (en)	2003-11-03	2009-04-30	Probiodrug Ag	Combinations useful for the treatment of neuronal disorders
EP1686994A2 (fr)	2003-11-17	2006-08-09	Novartis AG	Utilisation d'inhibiteurs de dipeptidyl-pepetidase iv
PL1715893T3 (pl)	2004-01-20	2010-03-31	Novartis Ag	Preparat prasowany bezpośrednio oraz sposób
CN1918119B (zh)	2004-02-05	2011-08-31	杏林制药株式会社	双环酯类衍生物
CN1918131B (zh)	2004-02-05	2011-05-04	前体生物药物股份公司	谷氨酰胺酰基环化酶抑制剂
FR2870538B1 (fr)	2004-05-19	2006-07-14	Servier Lab	Nouveaux derives de pyrrolidines et de thiazolidines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
NZ554515A (en)	2004-10-12	2009-12-24	Glenmark Pharmaceuticals Sa	Novel dipeptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and process for their preparation
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DOP2006000008A (es) *	2005-01-10	2006-08-31	Arena Pharm Inc	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
JP2008024592A (ja) *	2005-01-28	2008-02-07	Taisho Pharmaceut Co Ltd	シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法
EP1888562B1 (fr)	2005-04-22	2014-06-18	Alantos Pharmaceuticals Holding, Inc.	Inhibiteurs de la dipeptidyl peptidase iv
KR20080030652A (ko) *	2005-08-11	2008-04-04	에프. 호프만-라 로슈 아게	Ｄｐｐ-ｉｖ 억제제를 포함하는 약학 조성물
WO2007033350A1 (fr)	2005-09-14	2007-03-22	Takeda Pharmaceutical Company Limited	Inhibiteurs de la dipeptidyl peptidase permettant de traiter le diabete
CN101360723A (zh)	2005-09-16	2009-02-04	武田药品工业株式会社	制备嘧啶二酮衍生物的方法
GB0526291D0 (en)	2005-12-23	2006-02-01	Prosidion Ltd	Therapeutic method
US20090156465A1 (en)	2005-12-30	2009-06-18	Sattigeri Jitendra A	Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors
WO2007102286A1 (fr)	2006-03-08	2007-09-13	Kyorin Pharmaceutical Co., Ltd.	Procede de production d'un derive aminoacetylpyrrolidinecarbonitrile et intermediaire utilise pour sa production
CN101050194B (zh) *	2006-04-05	2013-08-21	上海恒瑞医药有限公司	双环辛烷类衍生物、其制备方法及其在医药上的用途
PE20071221A1 (es)	2006-04-11	2007-12-14	Arena Pharm Inc	Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
CN103323606A (zh) *	2006-04-11	2013-09-25	艾尼纳制药公司	使用gpr119受体鉴定可用于增加个体骨质量的化合物的方法
EP1852108A1 (fr)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Compositions d'inhibiteurs de la DPP IV
CN109503584A (zh)	2006-05-04	2019-03-22	勃林格殷格翰国际有限公司	多晶型
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
MX2009001043A (es)	2006-08-08	2009-02-06	Sanofi Aventis	Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para preparalas, medicamentos que comprenden estos compuestos y su uso.
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
JP5379692B2 (ja)	2006-11-09	2013-12-25	プロビオドルグエージー	潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
DK2091948T3 (da)	2006-11-30	2012-07-23	Probiodrug Ag	Nye inhibitorer af glutaminylcyclase
CN101230059B (zh) *	2007-01-23	2011-08-17	上海恒瑞医药有限公司	双环氮杂烷类衍生物、其制备方法及其在医药上的用途
CN101230058A (zh)	2007-01-23	2008-07-30	上海恒瑞医药有限公司	双环氮杂烷类衍生物、其制备方法及其在医药上的用途
DE102007005045B4 (de)	2007-01-26	2008-12-18	Sanofi-Aventis	Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
WO2008114857A1 (fr)	2007-03-22	2008-09-25	Kyorin Pharmaceutical Co., Ltd.	Procédé de préparation d'un dérivé d'aminoacétylpyrrolidinecarbonitrile
DK2142514T3 (da)	2007-04-18	2015-03-23	Probiodrug Ag	Thioureaderivater som glutaminylcyclase-inhibitorer
EP2155689B1 (fr)	2007-05-31	2015-07-08	Boehringer Ingelheim International GmbH	Antagonistes du récepteur ccr2 et leurs utilisations
GB0713602D0 (en) *	2007-07-12	2007-08-22	Syngenta Participations Ag	Chemical compounds
EP2025674A1 (fr)	2007-08-15	2009-02-18	sanofi-aventis	Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
US8338450B2 (en) *	2007-09-21	2012-12-25	Lupin Limited	Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors
BRPI0822143A2 (pt)	2008-01-23	2019-09-24	Jiangsu Hansoh Pharmaceutical Cio Ltd	derivados de dicicloaza-alcano, processos de preparação e usos médicos dos mesmos
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
EP2108960A1 (fr)	2008-04-07	2009-10-14	Arena Pharmaceuticals, Inc.	Procédés d'utilisation d'un récepteur couplé à protéine G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement des conditions modulées de secrétagogues BY (PYY) et composés utiles dans le traitement des conditions par PYY
US8470841B2 (en)	2008-07-09	2013-06-25	Sanofi	Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
BRPI0916997A2 (pt)	2008-08-06	2020-12-15	Boehringer Ingelheim International Gmbh	Inibidor de dpp-4 e seu uso
CA2732984A1 (fr)	2008-08-07	2010-02-11	Kyorin Pharmaceutical Co., Ltd.	Procede de fabrication d'un derive de bicyclo[2.2.2]octylamine
KR20110044780A (ko) *	2008-08-14	2011-04-29	교린 세이야꾸 가부시키 가이샤	안정화된 의약 조성물
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
WO2010054183A2 (fr) *	2008-11-07	2010-05-14	President And Fellows Of Harvard College	Colorants, compositions et procédés d’utilisation associés
WO2010068601A1 (fr)	2008-12-08	2010-06-17	Sanofi-Aventis	Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
SG172289A1 (en)	2008-12-19	2011-07-28	Boehringer Ingelheim Int	Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd
GB2483614B (en)	2009-06-18	2014-12-03	Lupin Ltd	2-Amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent dpp-iv inhibitors
AR077642A1 (es)	2009-07-09	2011-09-14	Arena Pharm Inc	Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
MX2012001729A (es)	2009-08-26	2012-06-13	Sanofi Sa	Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
BR112012008346B1 (pt)	2009-09-11	2021-12-21	Vivoryon Therapeutics N.V.	Derivados heterocíclicos, seu processo de preparação, e composição farmacêutica
KR20240090632A (ko)	2009-11-27	2024-06-21	베링거 인겔하임 인터내셔날 게엠베하	리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
AU2010332969B2 (en)	2009-12-17	2015-02-12	Centrexion Therapeutics Corporation	New CCR2 receptor antagonists and uses thereof
WO2011107530A2 (fr)	2010-03-03	2011-09-09	Probiodrug Ag	Nouveaux inhibiteurs
WO2011107494A1 (fr)	2010-03-03	2011-09-09	Sanofi	Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
ES2481823T3 (es)	2010-03-10	2014-07-31	Probiodrug Ag	Inhibidores heterocíclicos de glutaminil ciclasa (QC, EC 2.3.2.5)
JP2013523819A (ja)	2010-04-06	2013-06-17	アリーナファーマシューティカルズ，インコーポレイテッド	Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
JP5945532B2 (ja)	2010-04-21	2016-07-05	プロビオドルグエージー	グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
CA3070513C (fr)	2010-05-05	2023-01-03	Boehringer Ingelheim International Gmbh	Inhibiteur de dpp-4 a utiliser dans le traitement des transformations dela peau ou de la necrose
WO2011141477A1 (fr)	2010-05-12	2011-11-17	Boehringer Ingelheim International Gmbh	Nouveaux antagonistes du récepteur ccr2, leur procédé de production et leur utilisation en tant que médicaments
US8877745B2 (en)	2010-05-12	2014-11-04	Boehringer Ingelheim International Gmbh	CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011144501A1 (fr)	2010-05-17	2011-11-24	Boehringer Ingelheim International Gmbh	Antagonistes du récepteur ccr2 et leurs utilisations
EP2576542B1 (fr)	2010-05-25	2015-04-22	Boehringer Ingelheim International GmbH	Dérivés d'amide cycliques d'acides pyridazine-3-carboxyliques utiles dans le traitement de maladies respiratoires, liées à des douleurs, liées au système immunitaire et cardiovasculaires
US8962656B2 (en)	2010-06-01	2015-02-24	Boehringer Ingelheim International Gmbh	CCR2 antagonists
WO2011157827A1 (fr)	2010-06-18	2011-12-22	Sanofi	Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
AU2011305525B2 (en)	2010-09-22	2016-08-18	Arena Pharmaceuticals, Inc.	Modulators of the GPR119 receptor and the treatment of disorders related thereto
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
WO2012120054A1 (fr)	2011-03-08	2012-09-13	Sanofi	Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683704B1 (fr)	2011-03-08	2014-12-17	Sanofi	Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
WO2012120052A1 (fr)	2011-03-08	2012-09-13	Sanofi	Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
EP2683698B1 (fr)	2011-03-08	2017-10-04	Sanofi	Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
EP2683699B1 (fr)	2011-03-08	2015-06-24	Sanofi	Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8846666B2 (en)	2011-03-08	2014-09-30	Sanofi	Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120050A1 (fr)	2011-03-08	2012-09-13	Sanofi	Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, médicaments contenant ces composés et leur utilisation
EP2683703B1 (fr)	2011-03-08	2015-05-27	Sanofi	Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
EP2683700B1 (fr)	2011-03-08	2015-02-18	Sanofi	Dérivés d'oxathiazine tétra-substitués, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
DK2686313T3 (en)	2011-03-16	2016-05-02	Probiodrug Ag	Benzimidazole derivatives as inhibitors of glutaminyl cyclase
WO2012135570A1 (fr)	2011-04-01	2012-10-04	Arena Pharmaceuticals, Inc.	Modulateurs du récepteur gpr119 et traitement de troubles qui lui sont associés
US20140066369A1 (en)	2011-04-19	2014-03-06	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145604A1 (fr)	2011-04-22	2012-10-26	Arena Pharmaceuticals, Inc.	Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
WO2012145603A1 (fr)	2011-04-22	2012-10-26	Arena Pharmaceuticals, Inc.	Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
WO2012170702A1 (fr)	2011-06-08	2012-12-13	Arena Pharmaceuticals, Inc.	Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci
JP5786258B2 (ja)	2011-07-15	2015-09-30	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	新規かつ選択的なｃｃｒ２拮抗薬
WO2013037390A1 (fr)	2011-09-12	2013-03-21	Sanofi	Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2567959B1 (fr)	2011-09-12	2014-04-16	Sanofi	Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr)	2011-09-27	2013-04-04	Sanofi	Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
WO2013055910A1 (fr)	2011-10-12	2013-04-18	Arena Pharmaceuticals, Inc.	Modulateurs du récepteur gpr119 et traitement de troubles associés
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
JP2015520752A (ja) *	2012-05-11	2015-07-23	アッヴィ・インコーポレイテッド	Ｎａｍｐｔ阻害薬としてのピリダジンおよびピリジン誘導体
EP2849755A1 (fr)	2012-05-14	2015-03-25	Boehringer Ingelheim International GmbH	Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de troubles associés aux podocytes et/ou un syndrome néphrotique
WO2013174767A1 (fr)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
WO2014000629A1 (fr) *	2012-06-25	2014-01-03	广东东阳光药业有限公司	Dérivés hexahydropentaléno, leur procédé de préparation et leur utilisation en médecine
TWI500613B (zh)	2012-10-17	2015-09-21	Cadila Healthcare Ltd	新穎之雜環化合物
WO2014064215A1 (fr)	2012-10-24	2014-05-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Inhibiteurs de la kinase tpl2 pour prévenir ou traiter le diabète et favoriser la survie de cellules β
WO2014074668A1 (fr)	2012-11-08	2014-05-15	Arena Pharmaceuticals, Inc.	Modulateurs de gpr119 et traitement de troubles associés à ceux-ci
US9840489B2 (en)	2013-12-20	2017-12-12	Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China	Piperidine carboxamide compound, preparation method, and usage thereof
ES2950384T3 (es)	2014-02-28	2023-10-09	Boehringer Ingelheim Int	Uso médico de un inhibidor de DPP-4
CN104529858A (zh) *	2015-01-13	2015-04-22	佛山市赛维斯医药科技有限公司	含卤代金刚烷和酰胺类衍生物、其制备方法和用途
CN104529856A (zh) *	2015-01-13	2015-04-22	佛山市赛维斯医药科技有限公司	一种硝基金刚烷酰胺衍生物、其制备方法和用途
EP3053577A1 (fr) *	2015-02-09	2016-08-10	F. Hoffmann-La Roche AG	Composés pour le traitement du cancer
WO2016128343A1 (fr) *	2015-02-09	2016-08-18	F. Hoffmann-La Roche Ag	Composés pour le traitement d'un cancer
PL3265126T3 (pl)	2015-03-03	2021-12-06	Saniona A/S	Preparaty połączenia tesofensyny i metoprololu
KR20180006881A (ko)	2015-03-09	2018-01-19	인테크린 테라퓨틱스, 아이엔씨.	비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
WO2016151018A1 (fr)	2015-03-24	2016-09-29	INSERM (Institut National de la Santé et de la Recherche Médicale)	Méthode et composition pharmaceutique destinées à être utilisées dans le traitement du diabète
CA2990460C (fr)	2015-07-02	2023-10-17	Centrexion Therapeutics Corporation	Citrate de (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone
JP2019517542A (ja)	2016-06-10	2019-06-24	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	リナグリプチンおよびメトホルミンの組合せ
WO2018162722A1 (fr)	2017-03-09	2018-09-13	Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke	Inhibiteurs de dpp-4 à utiliser dans le traitement de fractures osseuses
KR20200036808A (ko)	2017-04-03	2020-04-07	코히러스 바이오사이언시스, 인크.	진행성 핵상 마비 치료를 위한 PPARγ 작용제
EP3461819B1 (fr)	2017-09-29	2020-05-27	Probiodrug AG	Inhibiteurs de la glutaminyl-cyclase
US11780821B2 (en)	2017-12-15	2023-10-10	Praxis Biotech LLC	Inhibitors of fibroblast activation protein
CN118955353A (zh) *	2024-10-14	2024-11-15	南京恒远科技开发有限公司	一种(s)-4,4-二氟-1-甘氨酰吡咯烷-2-氰基的合成方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2005A (en) *		1841-03-16		Improvement in the manner of constructing molds for casting butt-hinges
US2004A (en) *		1841-03-12		Improvement in the manner of constructing and propelling steam-vessels
US3225037A (en) *	1959-03-30	1965-12-21	Sterling Drug Inc	10-[(amino- and acylamino-1-piperidyl) lower-alkyl]-phenothiazines
GB1460389A (en) *	1974-07-25	1977-01-06	Pfizer Ltd	4-substituted quinazoline cardiac stimulants
US4302455A (en) *	1980-04-14	1981-11-24	Merck & Co., Inc.	2-(4-Aminopiperidino)pyrazines
US5001125A (en) *	1984-03-26	1991-03-19	Janssen Pharmaceutica N.V.	Anti-virally active pyridazinamines
JP2869561B2 (ja) *	1989-05-22	1999-03-10	大塚製薬株式会社	血小板粘着抑制剤
CA2106840A1 (fr) *	1992-09-25	1994-03-26	Marco Baroni	Heteroarylazetidines et -pyrrolidines, methode pour les preparer et compositions pharmaceutiques les renfermant
ES2079323B1 (es) *	1994-06-21	1996-10-16	Vita Invest Sa	Derivados de indol utiles para el tratamiento de la migraña, composicion y uso correspondientes.
UA51716C2 (uk) *	1996-07-08	2002-12-16	Авентіс Фармасьютікалз Продактс Інк.	Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
TW492957B (en) *	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
FR2780057B1 (fr) *	1998-06-18	2002-09-13	Sanofi Sa	Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
CN1636990A (zh) *	1999-05-21	2005-07-13	艾博特公司	用作中枢神经系统药物的杂环取代的氨基氮杂环
TW583185B (en)	2000-06-13	2004-04-11	Novartis Ag	N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
ES2311534T3 (es)	2000-08-10	2009-02-16	Mitsubishi Tanabe Pharma Corporation	Derivados de prolina y su uso como farmacos.
AU2001294197C1 (en) *	2000-10-06	2005-05-19	Tanabe Seiyaku Co., Ltd.	Aliphatic nitrogenous five-membered ring compounds
TWI243162B (en) *	2000-11-10	2005-11-11	Taisho Pharmaceutical Co Ltd	Cyanopyrrolidine derivatives
JP2002264450A (ja) *	2000-12-21	2002-09-18	Ricoh Co Ltd	画像処理ユニット、画像形成装置、画像形成方法及び画像処理システム
CA2433090A1 (fr) *	2000-12-27	2002-07-04	Kyowa Hakko Kogyo Co., Ltd.	Inhibiteur de dipeptidyl peptidase iv
GB0115517D0 (en) *	2001-06-25	2001-08-15	Ferring Bv	Novel antidiabetic agents
AU2002322344C1 (en) *	2001-06-27	2006-02-16	Smithkline Beecham Corporation	Fluoropyrrolidines as dipeptidyl peptidase inhibitors
ATE370943T1 (de) *	2001-06-27	2007-09-15	Smithkline Beecham Corp	Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren
RU2005101236A (ru)	2002-06-20	2005-06-27	Акцо Нобель Н.В. (NL)	(стабилизированные) перекисные композиции, флегматизированные определенным ненасыщенным флегматизирующим агентом
TW200401635A (en) *	2002-07-23	2004-02-01	Yamanouchi Pharma Co Ltd	2-Cyano-4-fluoropyrrolidine derivative or salt thereof
CN1706726A (zh) *	2004-02-17	2005-12-14	梅加特雷德国际公司	带发光部件的容器

2002
- 2002-03-06 HU HU0200849A patent/HUP0200849A2/hu unknown
2003
- 2003-03-04 AU AU2003209514A patent/AU2003209514B2/en not_active Ceased
- 2003-03-04 JP JP2003572969A patent/JP4559737B2/ja not_active Expired - Fee Related
- 2003-03-04 DE DE60329282T patent/DE60329282D1/de not_active Expired - Lifetime
- 2003-03-04 CN CNA038052636A patent/CN1639159A/zh active Pending
- 2003-03-04 EP EP03743452A patent/EP1487807B1/fr not_active Expired - Lifetime
- 2003-03-04 MX MXPA04008613A patent/MXPA04008613A/es active IP Right Grant
- 2003-03-04 BR BR0307960-0A patent/BR0307960A/pt not_active IP Right Cessation
- 2003-03-04 NZ NZ535662A patent/NZ535662A/en unknown
- 2003-03-04 PL PL03371099A patent/PL371099A1/xx not_active Application Discontinuation
- 2003-03-04 KR KR1020047013870A patent/KR100977898B1/ko not_active IP Right Cessation
- 2003-03-04 RS YU79004A patent/RS79004A/sr unknown
- 2003-03-04 CN CNA2006101640208A patent/CN1990486A/zh active Pending
- 2003-03-04 EA EA200401157A patent/EA007410B1/ru not_active IP Right Cessation
- 2003-03-04 AT AT03743452T patent/ATE443054T1/de not_active IP Right Cessation
- 2003-03-04 WO PCT/HU2003/000017 patent/WO2003074500A2/fr active Application Filing
- 2003-03-04 US US10/507,005 patent/US7348327B2/en not_active Expired - Fee Related
- 2003-03-04 CA CA2475312A patent/CA2475312C/fr not_active Expired - Fee Related
- 2003-03-05 AR ARP030100723A patent/AR038868A1/es unknown
- 2003-03-06 TW TW092104743A patent/TWI250978B/zh not_active IP Right Cessation
- 2003-04-03 UA UA20041008080A patent/UA78291C2/uk unknown
2004
- 2004-07-29 IL IL163286A patent/IL163286A/en not_active IP Right Cessation
- 2004-07-29 MA MA27806A patent/MA27105A1/fr unknown
- 2004-07-29 TN TNP2004000141A patent/TNSN04141A1/en unknown
- 2004-08-13 ZA ZA200406467A patent/ZA200406467B/en unknown
- 2004-09-02 IS IS7434A patent/IS7434A/is unknown
- 2004-09-03 EC EC2004005274A patent/ECSP045274A/es unknown
- 2004-10-04 HR HR20040910A patent/HRP20040910A2/hr not_active Application Discontinuation
- 2004-10-05 NO NO20044221A patent/NO20044221L/no not_active Application Discontinuation
2006
- 2006-09-07 IL IL177933A patent/IL177933A0/en unknown
2008
- 2008-03-05 US US12/042,595 patent/US7655663B2/en not_active Expired - Fee Related
2010
- 2010-02-01 US US12/697,762 patent/US8063045B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US8063045B2 (en)	2011-11-22
BR0307960A (pt)	2005-02-15
US7655663B2 (en)	2010-02-02
US20080161310A1 (en)	2008-07-03
EA007410B1 (ru)	2006-10-27
CA2475312C (fr)	2011-10-18
AU2003209514B2 (en)	2009-07-16
HUP0200849D0 (fr)	2002-05-29
EP1487807B1 (fr)	2009-09-16
US20050130981A1 (en)	2005-06-16
AR038868A1 (es)	2005-02-02
TW200303860A (en)	2003-09-16
ECSP045274A (es)	2004-10-26
HUP0200849A2 (hu)	2004-08-30
DE60329282D1 (de)	2009-10-29
CN1639159A (zh)	2005-07-13
WO2003074500A3 (fr)	2003-12-18
KR20040091102A (ko)	2004-10-27
US20100210838A1 (en)	2010-08-19
ZA200406467B (en)	2005-06-22
PL371099A1 (en)	2005-06-13
MXPA04008613A (es)	2005-06-08
CA2475312A1 (fr)	2003-09-12
IL163286A (en)	2007-06-03
JP2005529078A (ja)	2005-09-29
AU2003209514A1 (en)	2003-09-16
TNSN04141A1 (en)	2007-03-12
EP1487807A2 (fr)	2004-12-22
RS79004A (en)	2006-12-15
IS7434A (is)	2004-09-02
CN1990486A (zh)	2007-07-04
JP4559737B2 (ja)	2010-10-13
ATE443054T1 (de)	2009-10-15
NO20044221L (no)	2004-12-06
EA200401157A1 (ru)	2005-06-30
NZ535662A (en)	2007-05-31
UA78291C2 (en)	2007-03-15
KR100977898B1 (ko)	2010-08-24
HRP20040910A2 (en)	2006-02-28
US7348327B2 (en)	2008-03-25
TWI250978B (en)	2006-03-11
WO2003074500A2 (fr)	2003-09-12
IL177933A0 (en)	2006-12-31

Publication	Publication Date	Title
MA27105A1 (fr)	2004-12-20	Nouveaux composes
MA26216A1 (fr)	2004-07-01	Nouveaux composes
DE602004018654D1 (de)	2009-02-05	Se
ATE457980T1 (de)	2010-03-15	Aryloxime
ATE534648T1 (de)	2011-12-15	C-6-modifizierte indazolylpyrrolotriazine
ATE318817T1 (de)	2006-03-15	Aza-arylpiperazine
MA28933B1 (fr)	2007-10-01	Nouveaux composes
NO20044046L (no)	2004-11-15	Substituerte hydroksyetylaminer
DE60326590D1 (de)	2009-04-23	Tend lamotrigin
NO20044215L (no)	2004-10-05	Radioosotopgenerator
NO20052239D0 (no)	2005-05-06	Fast preparat
ATE349458T1 (de)	2007-01-15	Etonogestrelester
ATE496887T1 (de)	2011-02-15	Substituierte 5-aminomethyl-1h-pyrrol-2-carbons ureamide
DE60318029D1 (de)	2008-01-24	Zünder
NO20034599L (no)	2005-04-15	Brokonstruksjon
ATA4142004A (de)	2005-12-15	Trägerverbau
NO20034600L (no)	2005-04-15	Brokonstruksjon
ATE444953T1 (de)	2009-10-15	Substituierte spirobenzazepine
ATE469773T1 (de)	2010-06-15	Zugöse
EP1658301A4 (fr)	2009-12-09	Composes n-desmethyl-11-desoxyerythromycine-n-substitues
ATA19152002A (de)	2004-11-15	Hubkupplung
FR2840006B1 (fr)	2005-01-21	Construction demontable
ATE350379T1 (de)	2007-01-15	Substituierte benzdioxepine
ITGE20020039A1 (it)	2003-11-17	Bicicletta
AT5889U3 (de)	2003-04-25	Brennholzspleisser